| P2093 | author name string | Andrew M Davidoff | |
| | Amit C Nathwani | |
| | Paxton V Dickson | |
| P2860 | cites work | Endostatin: an endogenous inhibitor of angiogenesis and tumor growth | Q24315369 |
| | Antiangiogenic gene therapy of cancer: recent developments | Q24803786 |
| | Tumor angiogenesis: therapeutic implications | Q27860595 |
| | Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 |
| | Angiogenesis in cancer and other diseases | Q27861015 |
| | Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth | Q28203327 |
| | LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1 | Q28210584 |
| | Role of angiogenesis in tumor growth and metastasis | Q29614309 |
| | Molecular regulation of vessel maturation | Q29614540 |
| | Angiogenesis in health and disease | Q29614541 |
| | Vascular-specific growth factors and blood vessel formation | Q29614780 |
| | Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma | Q29615947 |
| | Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis | Q29620559 |
| | VEGF165 antisense RNA suppresses oncogenic properties of human esophageal squamous cell carcinoma | Q30724216 |
| | Progress in antiangiogenic gene therapy of cancer | Q30927477 |
| | Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells | Q31077883 |
| | Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. | Q33187344 |
| | New directions in liposome gene delivery | Q33721388 |
| | Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma | Q34038480 |
| | Clinical translation of angiogenesis inhibitors | Q34152769 |
| | Gene therapy: trials and tribulations | Q34186665 |
| | Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer | Q34530109 |
| | Mechanisms of normal and tumor-derived angiogenesis | Q34592513 |
| | Complex roles of tissue inhibitors of metalloproteinases in cancer | Q34596110 |
| | Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers | Q34608643 |
| | Cancer gene therapy with tissue inhibitors of metalloproteinases (TIMPs). | Q34729659 |
| | Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma | Q34733110 |
| | In vivo characteristics of cationic liposomes as delivery vectors for gene therapy | Q35012639 |
| | Tumor angiogenesis and accessibility: role of vascular endothelial growth factor | Q35040013 |
| | Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications | Q35040017 |
| | Promises and pitfalls of anti-angiogenic therapy in clinical trials | Q35076995 |
| | Progress and problems with the use of viral vectors for gene therapy | Q35120176 |
| | Fundamental Concepts of the Angiogenic Process | Q35577243 |
| | Vascular targeting agents as cancer therapeutics | Q35647684 |
| | Endothelial cell development, vasculogenesis, angiogenesis, and tumor neovascularization: an update | Q35701345 |
| | Tumor progression: the effects of thrombospondin-1 and -2. | Q35749722 |
| | Recent developments in the regulation of the angiogenic switch by cellular stress factors in tumors | Q36003512 |
| | Improving delivery of antineoplastic agents with anti-vascular endothelial growth factor therapy | Q36064914 |
| | Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus | Q36159178 |
| | Prediction of metastasis risk (11 year follow-up) using VEGF-R1, VEGF-R2, Tie-2/Tek and CD105 expression in breast cancer (n=905). | Q36694709 |
| | Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody | Q37051843 |
| | Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer | Q37219981 |
| | Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis | Q37340349 |
| | Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases | Q37378717 |
| | A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model | Q40438059 |
| | Radiation-enhanced endostatin gene expression and effects of combination treatment | Q40445708 |
| | Careful decoy receptor titering is required to inhibit tumor angiogenesis while avoiding adversely altering VEGF bioavailability. | Q40466380 |
| | Adeno-associated viral vector-mediated expression of endostatin inhibits tumor growth and metastasis in an orthotropic pancreatic cancer model in hamsters. | Q40502625 |
| | Restriction of neuroblastoma angiogenesis and growth by interferon-alpha/beta | Q40527457 |
| | Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12. | Q40538206 |
| | Longterm recombinant adeno-associated, virus-mediated, liver-generated expression of an angiogenesis inhibitor improves survival in mice with disseminated neuroblastoma | Q40541729 |
| | Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors | Q40550209 |
| | Vascular progenitors derived from murine bone marrow stromal cells are regulated by fibroblast growth factor and are avidly recruited by vascularizing tumors | Q40572542 |
| | A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles | Q40582334 |
| | Anti-tumor efficacy of human angiostatin using liver-mediated adeno-associated virus gene therapy | Q40596034 |
| | Gene therapy for hepatocellular carcinoma using non-viral vectors composed of bis guanidinium-tren-cholesterol and plasmids encoding the tissue inhibitors of metalloproteinases TIMP-2 and TIMP-3. | Q40644810 |
| | The application of an anti-angiogenic gene (thrombospondin-1) in the treatment of human prostate cancer xenografts | Q40823128 |
| | Gene therapy-mediated expression by tumor cells of the angiogenesis inhibitor flk-1 results in inhibition of neuroblastoma growth in vivo | Q40833199 |
| | Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity | Q41133661 |
| | Why do so many cancer patients fail to respond to interferon therapy? | Q41480595 |
| | Inhibition of angiogenesis in vivo by interleukin 12. | Q41665801 |
| | Gene therapy strategies for tumor antiangiogenesis | Q41714494 |
| | Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain | Q42280576 |
| | Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography | Q45747418 |
| | Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer [seecomments] | Q45854824 |
| | Adenovirus-mediated gene therapy with an antiangiogenic fragment of thrombospondin-1 inhibits human leukemia xenograft growth in nude mice | Q45862837 |
| | The treatment of established intracranial tumors by in situ retroviral IFN-gamma transfer | Q45872450 |
| | Viral vector-mediated transduction of a modified thrombospondin-2 cDNA inhibits tumor growth and angiogenesis | Q45874860 |
| | Effect of in situ retroviral interleukin-4 transfer on established intracranial tumors | Q48267756 |
| | The paracrine role of tumour-derived mIL-4 on tumour-associated endothelium | Q48638541 |
| | Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. | Q50626711 |
| | Enforced expression of tissue inhibitor of matrix metalloproteinase-3 affects functional capillary morphogenesis and inhibits tumor growth in a murine tumor model. | Q51700781 |
| | Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice. | Q52488991 |
| P433 | issue | 4 | |
| P921 | main subject | gene therapy | Q213901 |
| | angiogenesis inhibitor | Q574834 |
| | cancer gene therapy | Q124350675 |
| P304 | page(s) | 331-341 | |
| P577 | publication date | 2005-08-01 | |
| P1433 | published in | Technology in Cancer Research and Treatment | Q15755758 |
| P1476 | title | Delivery of antiangiogenic agents for cancer gene therapy | |
| P478 | volume | 4 | |